HDAC9 Deficiency Upregulates cGMP-dependent Kinase II to Mitigate Neuronal Apoptosis in Ischemic Stroke
Translational Stroke Research · 2025
DOI: 10.1007/s12975-024-01272-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Stroke Research, 2025. Verfasst von Haoran Lin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, the Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88 Jiefang Road, Hangzhou, 310009, China. Hauptthemen laut MEDLINE: Apoptosis, Neurons, Histone Deacetylases, Ischemic Stroke. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Project of the Zhejiang Provincial Health Commission, National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province.
Themen: Schlaganfall
Abstract (Originalsprache)
Histone deacetylase 9 (HDAC9) is implicated in ischemic stroke by genome-wide association studies. We conducted a series of experiments using a mouse model of ischemic stroke (middle cerebral artery occlusion followed by reperfusion) to examine the potential role of HDAC9. Briefly, HDAC9 was upregulated in the penumbra. Deletion of HDAC9 from neurons reduced infarction volume, inhibited neuronal apoptosis in the penumbra, and improved neurological outcomes. HDAC9 knockout from neurons in the penumbra upregulated cGMP-dependent kinase II (cGK II), blocking which abrogated the protective effects of HDAC9 deletion. Mechanistically, HDAC9 interacts with the transcription factor MEF2, thereby inhibiting MEF2's binding to the promoter region of the cGK II gene, which results in the suppression of cGK II expression. Inhibiting the interaction between HDAC9 and MEF2 by BML210 upregulated cGK II and attenuated ischemic injury in mice. These results encourage targeting the HDAC9-MEF2 interaction in developing novel therapy against ischemic stroke.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, the Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88 Jiefang Road, Hangzhou, 310009, China.
- College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.
- Department of Pharmacy, the Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88 Jiefang Road, Hangzhou, 310009, China. haibindai@zju.edu.cn.
- Clinical Pharmacy Research Center, Zhejiang University, Hangzhou, 310058, China. haibindai@zju.edu.cn.
Förderung
- Project of the Zhejiang Provincial Health Commission
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Lin, H., Bei, Y., Shen, Z., Wei, T., Ge, Y., Yu, L., Xu, H., He, W., Dai, Y., Yao, D., & Dai, H. (2025). HDAC9 Deficiency Upregulates cGMP-dependent Kinase II to Mitigate Neuronal Apoptosis in Ischemic Stroke. Translational Stroke Research. https://doi.org/10.1007/s12975-024-01272-7
Vancouver
Lin H, Bei Y, Shen Z, Wei T, Ge Y, Yu L, et al. HDAC9 Deficiency Upregulates cGMP-dependent Kinase II to Mitigate Neuronal Apoptosis in Ischemic Stroke. Translational Stroke Research. 2025. doi:10.1007/s12975-024-01272-7
BibTeX
@article{Lin2025,
author = {Lin, Haoran and Bei, Yun and Shen, Zexu and Wei, Taofeng and Ge, Yuyang and Yu, Lingyan and Xu, Huimin and He, Wei and Dai, Yunjian and Yao, Difei and Dai, Haibin},
title = {HDAC9 Deficiency Upregulates cGMP-dependent Kinase II to Mitigate Neuronal Apoptosis in Ischemic Stroke},
journal = {Translational Stroke Research},
year = {2025},
doi = {10.1007/s12975-024-01272-7}
}
EUVIMED